Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor DayDelivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC BrandsWidened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS RangeDUBLIN, May 7, 2025 /PRNewswire/ --First Quarter 2025 Highlights: Net sales of $1.04 billion declined ...